Want to see HK:1521 full AI Analyst Report?
1521 Stock Chart & Stats
HK$1.03
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$1.03
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.68 - HK$1.50
Previous CloseN/A
Volume454.00K
Average Volume (3M)468.13K
Market Cap
HK$2.57B
Enterprise ValueHK$2.73K
Total Cash (Recent Filing)HK$39.14M
Total Debt (Recent Filing)HK$127.60M
Price to Earnings (P/E)48.9
Beta1.23
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,042,075,000
10 Day Avg. Volume431,000
30 Day Avg. Volume468,133
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.76
Price to Sales (P/S)1.03
P/FCF Ratio8.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)HK$278.57M
Bulls Say, Bears Say
Bulls Say
Long-term Revenue ExpansionStrong multi-year revenue expansion indicates increasing customer demand and market reach. Although recent growth has been uneven, the 2025 rebound suggests the company retains a meaningful platform for continued business development.
Manageable LeverageModerate and improving leverage provides financial resilience and preserves flexibility to fund operations or growth. Lower debt in 2025 reduces balance-sheet pressure and limits the risk that interest or refinancing needs constrain future investment.
Consistent Operating Cash FlowPersistent positive operating cash flow demonstrates that the core business generates cash to support working capital, obligations, and reinvestment. This offers a durable source of financial flexibility even when reported profitability fluctuates.
Bears Say
Structural Margin CompressionThe sustained decline in gross and net margins shows that revenue growth is producing less profit than in earlier years. Unless pricing, mix, or operating efficiency improves, weaker margins can limit earnings growth and reduce resilience.
Volatile Free Cash FlowVolatile free cash flow weakens confidence in earnings quality and makes internally funded investment less predictable. The sharp 2025 decline, despite improved earnings, could constrain acquisitions, capacity expansion, or shareholder returns.
Low Return On EquityVery low ROE indicates that the company is generating limited profit from its equity base despite maintaining acceptable leverage. Persistently weak capital productivity can reduce long-term value creation and leave less room to absorb operating setbacks.
Frontage Holdings Corp. News
1521 FAQ
What was Frontage Holdings Corp.’s price range in the past 12 months?
Frontage Holdings Corp. lowest stock price was HK$0.68 and its highest was HK$1.50 in the past 12 months.
What is Frontage Holdings Corp.’s market cap?
Frontage Holdings Corp.’s market cap is HK$2.57B.
When is Frontage Holdings Corp.’s upcoming earnings report date?
Frontage Holdings Corp.’s upcoming earnings report date is Aug 28, 2026 which is in 7 days.
How were Frontage Holdings Corp.’s earnings last quarter?
Currently, no data Available
Is Frontage Holdings Corp. overvalued?
According to Wall Street analysts Frontage Holdings Corp.’s price is currently Overvalued.
Does Frontage Holdings Corp. pay dividends?
Frontage Holdings Corp. does not currently pay dividends.
What is Frontage Holdings Corp.’s EPS estimate?
Frontage Holdings Corp.’s EPS estimate is 0.
How many shares outstanding does Frontage Holdings Corp. have?
Frontage Holdings Corp. has 2,042,075,000 shares outstanding.
What happened to Frontage Holdings Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Frontage Holdings Corp.?
Currently, no hedge funds are holding shares in HK:1521
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Frontage Holdings Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
91.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.07%
Trailing 12-Months
Company Description
Frontage Holdings Corp.
Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequivalence assessments. The company's diverse service portfolio includes specialized laboratory testing, covering method development, validation, sample analysis, and central laboratory operations. They also provide Chemistry, Manufacturing, and Control (CMC) support, assisting with drug product development and analysis, as well as the provision of clinical trial materials. Furthermore, Frontage offers Drug Metabolism and Pharmacokinetics (DMPK) services, encompassing study design, execution, and data interpretation for tasks such as structural optimization in early discovery, pharmacokinetic studies in rodents, and non-GLP bioanalytical analyses. Their capabilities extend to comprehensive safety and toxicology evaluations through both in vitro and in vivo studies, as well as robust bioequivalence (BE) services from design through reporting. Additionally, the company undertakes chemistry services, including contract research and custom synthesis, and provides an array of clinical services like early-stage clinical trials, BE/BA studies, biometrics, and data management. Frontage maintains a global operational footprint, with a presence in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―





